Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:      
Net loss $ (1,091) $ (2,710) $ (3,501)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization 252 355 363
Gain on the sale of fixed assets 0 (28) 0
Reduction of payment obligation, settlement benefit (1,024) 0 0
Share-based compensation expense 246 631 192
Changes in operating assets and liabilities:      
Accounts receivable (2,190) 1,602 (1,222)
Inventory 637 (1,006) (277)
Prepaid expenses and other assets (940) (864) (68)
Accounts payable 411 396 (219)
Accrued advertising and other allowances (199) (565) 1,384
Accrued royalties and commissions (2,100) 0 0
Other operating assets and liabilities, net 269 81 (201)
Net cash used in operating activities (5,729) (2,108) (3,549)
Cash flows from investing activities:      
Capital expenditures (310) (300) (153)
Acquisition of product license 0 0 (1,000)
Proceeds from the sale of fixed assets 0 166 0
Net cash flows used in investing activities (310) (134) (1,153)
Cash flows from financing activities:      
Proceeds from the exercise of stock options 0 0 133
Proceeds from issuance of common stock 1,070 0 0
Purchase of treasury stock 0 (449) 0
Net cash provided by (used in) financing activities 1,070 (449) 133
Net decrease in cash and cash equivalents (4,969) (2,691) (4,569)
Cash and cash equivalents at beginning of year 5,541 8,232 12,801
Cash and cash equivalents at end of year 572 5,541 8,232
Supplemental disclosures of cash flow information:      
Income taxes paid 0 0 34
Common stock issued to Phosphagenics Limited pursuant to a product license agreement 0 0 2,577
Common stock issued, in lieu of cash, as payment of accrued compensation $ 0 $ 294 $ 0